0 206

Cited 0 times in

Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials

Authors
 Soojin Lim  ;  Seoyeon Park  ;  Ai Koyanagi  ;  Jae Won Yang  ;  Louis Jacob  ;  Dong Keon Yon  ;  Seung Won Lee  ;  Min Seo Kim  ;  Jae Il Shin  ;  Lee Smith 
Citation
 PHARMACOLOGICAL RESEARCH, Vol.176 : 106052, 2022-02 
Journal Title
PHARMACOLOGICAL RESEARCH
ISSN
 1043-6618 
Issue Date
2022-02
MeSH
Humans ; Melatonin / therapeutic use* ; Mental Disorders / drug therapy ; Metabolic Diseases / drug therapy ; Pain, Postoperative / drug therapy ; Randomized Controlled Trials as Topic ; Sleep Wake Disorders / drug therapy
Keywords
Alprazolam (PubChem CID:2118) ; Clinical outcome ; Clozapine (PubChem CID:135398737) ; Inositol (PubChem CID:892) ; Melatonin ; Melatonin (PubChem CID:896) ; Midazolam (PubChem CID:4192) ; Olanzapine (PubChem CID:135398745) ; Oxazepam (PubChem CID:4616) ; Quetiapine (PubChem CID:5002) ; Randomized controlled trial ; Risperidone (PubChem CID:5073) ; Umbrella review
Abstract
Various melatonin supplementations have been developed to improve health outcomes in various clinical conditions. Thus, we sought to evaluate and summarize the effect of melatonin treatments in clinical settings for health outcomes. We searched PubMed/Medline, Embase, and Cochrane Library from inception to 4 February 2021. We included meta-analyses of randomized controlled trials investigating the melatonin intervention for any health outcome. Based on the different effect sizes of each meta-analysis, we calculated random models' standardized mean differences or risk ratios. We observed robust evidence supported by statistical significance with non-considerable heterogeneity between studies for sleep-related problems, cancer, surgical patients, and pregnant women. Patients with sleep disorder, sleep onset latency (SMD 0.33, 95% CI: 0.10 - 0.56, P < 0.01) were significantly improved whereas no clear evidence was shown with sleep efficiency (1.10, 95% CI: -0.26 to 2.45). The first analgesic requirement time (SMD 5.81, 95% CI: 2.57-9.05, P < 0.001) of surgical patients was distinctly improved. Female patients under artificial reproductive technologies had significant increase in the top-quality embryos (SMD 0.53, 95% CI: 0.27 - 0.79, P < 0.001), but no statistically clear evidence was found in the live birth rate (SMD 1.20, 95% CI: 0.83 - 1.72). Survival at one year (RR 1.90, 95% CI: 1.28 - 2.83, P < 0.005) significantly increased with cancer patients. Research on melatonin interventions to treat clinical symptoms and sleep problems among diverse health conditions was identified and provided considerable evidence. Future well-designed randomized clinical trials of high quality and subgroup quantitative analyses are essential.
Full Text
https://www.sciencedirect.com/science/article/pii/S1043661821006368?via%3Dihub
DOI
10.1016/j.phrs.2021.106052
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Shin, Jae Il(신재일) ORCID logo https://orcid.org/0000-0003-2326-1820
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188746
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links